Subscribe
shutterstock_1492764635_michael_vi
Michael Vi / Shutterstock.com
4 February 2021Big PharmaAlex Baldwin

Coherus secures toripalimab rights for US and Canada

Coherus Biosciences has signed a deal with Chinese biopharmaceutical company Shanghai Junshi Biosciences for the development and commercialisation rights to toripalimab, Junshi’s PD-1 inhibitor, in the US and Canada.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Amgen sets sights on Coherus over biologic drug
12 May 2017   Amgen has set its sights on Coherus Biosciences, a biosimilar maker, for allegedly infringing a patent concerning a process for purifying proteins.
Americas
Coherus attempts to dismiss Amgen’s Neulasta suit
12 June 2017   Coherus BioSciences has asked a court to dismiss patent infringement allegations brought against it by Amgen.
Americas
Fed Circuit cancels skin cancer detection patent
22 February 2021   The US Court of Appeals for the Federal Circuit has cancelled claims of a Melanoscan patent covering methods of detecting skin cancer.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Amgen sets sights on Coherus over biologic drug
12 May 2017   Amgen has set its sights on Coherus Biosciences, a biosimilar maker, for allegedly infringing a patent concerning a process for purifying proteins.
Americas
Coherus attempts to dismiss Amgen’s Neulasta suit
12 June 2017   Coherus BioSciences has asked a court to dismiss patent infringement allegations brought against it by Amgen.
Americas
Fed Circuit cancels skin cancer detection patent
22 February 2021   The US Court of Appeals for the Federal Circuit has cancelled claims of a Melanoscan patent covering methods of detecting skin cancer.

More on this story

Americas
Amgen sets sights on Coherus over biologic drug
12 May 2017   Amgen has set its sights on Coherus Biosciences, a biosimilar maker, for allegedly infringing a patent concerning a process for purifying proteins.
Americas
Coherus attempts to dismiss Amgen’s Neulasta suit
12 June 2017   Coherus BioSciences has asked a court to dismiss patent infringement allegations brought against it by Amgen.
Americas
Fed Circuit cancels skin cancer detection patent
22 February 2021   The US Court of Appeals for the Federal Circuit has cancelled claims of a Melanoscan patent covering methods of detecting skin cancer.

More features

President Trump 2.0: Five major areas to watch
China’s new policies on foreign investment in healthcare and biotech
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug